Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.

Abstract

Liraglutide is associated with blood pressure reduction in patients with type 2 diabetes. However, it is not known whether this blood pressure reduction can be predicted prior to treatment initiation, and to what extent it correlates with weight loss and with improved glycemic control during follow-up. We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo. We evaluated various baseline variables as potential predictors of systolic blood pressure (SBP) reduction, and evaluated whether changes in SBP correlated with weight loss and with improved glycemic control. A greater reduction in SBP among liraglutide-treated patients was predicted by higher baseline values of SBP (P<0.0001) and diastolic blood pressure (P=0.012), and by lower baseline values of mean glucose measured by continuous glucose monitoring (CGM; P=0.044), and serum fasting C-peptide (P=0.015). The regression coefficients differed significantly between the liraglutide group and the placebo group only for diastolic blood pressure (P=0.037) and mean CGM (P=0.021). During the trial period, SBP reduction correlated directly with change in body weight and BMI, but not with change in HbA1c. We conclude that patients with lower mean CGM values at baseline responded to liraglutide with a larger reduction in SBP, and that improved HbA1c during follow-up was not associated with reductions of SBP. Our data suggest that some patients with type 2 diabetes may benefit from liraglutide in terms of weight and SBP reduction.